An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder

Yuichi Esaki, Tsuyoshi Kitajima, Shigefumi Koike, Hiroshige Fujishiro, Yasuyo Iwata, Akiko Tsuchiya, Marina Hirose, Nakao Iwata

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Study Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by REM sleep without atonia and elaborate motor activity in association with dream mentation. The melatonin receptor agonist ramelteon has been documented as being effective in two patients with secondary RBD. However, there are no reports on ramelteon treatment for idiopathic RBD. Methods: In an open-labeled trial, we treated 12 consecutive patients with idiopathic RBD for at least 4 w with 8 mg ramelteon given within 30 min before bedtime. Results: Ramelteon treatment did not have a clear effect on REM sleep without atonia or an RBD severity scale measured by video-supported polysomnography. However, clinical assessment using a visual analog scale showed a trend toward significance and there were also definitely positive changes in some individual cases. Ramelteon was well tolerated in most patients, with minor side effects. Conclusions: Considering that ramelteon is associated with few side effects, further study may ascertain whether patients with RBD could be effectively treated by ramelteon, especially when clonazepam may not be suitable due to its side effects. Commentary: A commentary on this article appears in this issue on page 643.

Original languageEnglish
Pages (from-to)689-693
Number of pages5
JournalJournal of Clinical Sleep Medicine
Volume12
Issue number5
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

REM Sleep Behavior Disorder
REM Sleep Parasomnias
Melatonin Receptors
Clonazepam
Polysomnography
REM Sleep
ramelteon
Visual Analog Scale
Sleep
Motor Activity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Neurology
  • Clinical Neurology

Cite this

Esaki, Yuichi ; Kitajima, Tsuyoshi ; Koike, Shigefumi ; Fujishiro, Hiroshige ; Iwata, Yasuyo ; Tsuchiya, Akiko ; Hirose, Marina ; Iwata, Nakao. / An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder. In: Journal of Clinical Sleep Medicine. 2016 ; Vol. 12, No. 5. pp. 689-693.
@article{64963f9d6f584ad18e72714d97eae91d,
title = "An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder",
abstract = "Study Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by REM sleep without atonia and elaborate motor activity in association with dream mentation. The melatonin receptor agonist ramelteon has been documented as being effective in two patients with secondary RBD. However, there are no reports on ramelteon treatment for idiopathic RBD. Methods: In an open-labeled trial, we treated 12 consecutive patients with idiopathic RBD for at least 4 w with 8 mg ramelteon given within 30 min before bedtime. Results: Ramelteon treatment did not have a clear effect on REM sleep without atonia or an RBD severity scale measured by video-supported polysomnography. However, clinical assessment using a visual analog scale showed a trend toward significance and there were also definitely positive changes in some individual cases. Ramelteon was well tolerated in most patients, with minor side effects. Conclusions: Considering that ramelteon is associated with few side effects, further study may ascertain whether patients with RBD could be effectively treated by ramelteon, especially when clonazepam may not be suitable due to its side effects. Commentary: A commentary on this article appears in this issue on page 643.",
author = "Yuichi Esaki and Tsuyoshi Kitajima and Shigefumi Koike and Hiroshige Fujishiro and Yasuyo Iwata and Akiko Tsuchiya and Marina Hirose and Nakao Iwata",
year = "2016",
month = "1",
day = "1",
doi = "10.5664/jcsm.5796",
language = "English",
volume = "12",
pages = "689--693",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "5",

}

An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder. / Esaki, Yuichi; Kitajima, Tsuyoshi; Koike, Shigefumi; Fujishiro, Hiroshige; Iwata, Yasuyo; Tsuchiya, Akiko; Hirose, Marina; Iwata, Nakao.

In: Journal of Clinical Sleep Medicine, Vol. 12, No. 5, 01.01.2016, p. 689-693.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An open-labeled trial of ramelteon in idiopathic rapid eye movement sleep behavior disorder

AU - Esaki, Yuichi

AU - Kitajima, Tsuyoshi

AU - Koike, Shigefumi

AU - Fujishiro, Hiroshige

AU - Iwata, Yasuyo

AU - Tsuchiya, Akiko

AU - Hirose, Marina

AU - Iwata, Nakao

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Study Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by REM sleep without atonia and elaborate motor activity in association with dream mentation. The melatonin receptor agonist ramelteon has been documented as being effective in two patients with secondary RBD. However, there are no reports on ramelteon treatment for idiopathic RBD. Methods: In an open-labeled trial, we treated 12 consecutive patients with idiopathic RBD for at least 4 w with 8 mg ramelteon given within 30 min before bedtime. Results: Ramelteon treatment did not have a clear effect on REM sleep without atonia or an RBD severity scale measured by video-supported polysomnography. However, clinical assessment using a visual analog scale showed a trend toward significance and there were also definitely positive changes in some individual cases. Ramelteon was well tolerated in most patients, with minor side effects. Conclusions: Considering that ramelteon is associated with few side effects, further study may ascertain whether patients with RBD could be effectively treated by ramelteon, especially when clonazepam may not be suitable due to its side effects. Commentary: A commentary on this article appears in this issue on page 643.

AB - Study Objectives: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by REM sleep without atonia and elaborate motor activity in association with dream mentation. The melatonin receptor agonist ramelteon has been documented as being effective in two patients with secondary RBD. However, there are no reports on ramelteon treatment for idiopathic RBD. Methods: In an open-labeled trial, we treated 12 consecutive patients with idiopathic RBD for at least 4 w with 8 mg ramelteon given within 30 min before bedtime. Results: Ramelteon treatment did not have a clear effect on REM sleep without atonia or an RBD severity scale measured by video-supported polysomnography. However, clinical assessment using a visual analog scale showed a trend toward significance and there were also definitely positive changes in some individual cases. Ramelteon was well tolerated in most patients, with minor side effects. Conclusions: Considering that ramelteon is associated with few side effects, further study may ascertain whether patients with RBD could be effectively treated by ramelteon, especially when clonazepam may not be suitable due to its side effects. Commentary: A commentary on this article appears in this issue on page 643.

UR - http://www.scopus.com/inward/record.url?scp=84969217499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969217499&partnerID=8YFLogxK

U2 - 10.5664/jcsm.5796

DO - 10.5664/jcsm.5796

M3 - Article

VL - 12

SP - 689

EP - 693

JO - Journal of Clinical Sleep Medicine

JF - Journal of Clinical Sleep Medicine

SN - 1550-9389

IS - 5

ER -